文献速递主动脉外科

胸部分支内假体上市后真实世界应用:广泛适用于各类患者

Initial Post-Commercialization Experience Using a Thoracic Branch Endoprosthesis: Broad Application to Real-World Patients.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-01-01

该单中心回顾性队列研究评估了Gore胸部分支内假体(TBE)在55例真实世界患者中的早期结果,其中49.1%为主动脉夹层,29.1%在0区部署。技术成功率100%,手术死亡率3.6%,无卒中或瘫痪,随访期内内漏发生率16.4%。结论认为TBE在多种主动脉病变和部署区域中安全且通用。

要点

  • TBE在0区、1区及夹层等超适应症使用中技术成功率达100%。
  • 手术死亡率3.6%,无卒中或永久性瘫痪,1例暂时性下肢轻瘫经脊髓引流缓解。
  • 随访期内漏发生率16.4%,其中6例需再次干预。

核心结论

  • Gore TBE装置在真实世界多种主动脉病变及部署区域中显示安全性和通用性。
  • 需进一步随访评估修复耐久性。

研究设计与样本

  • 回顾性单中心队列研究,纳入2022年9月至2024年9月连续55例使用Gore TBE行主动脉修复的患者。

主要发现

  • 适应证:动脉瘤26例(47.3%),夹层27例(49.1%,其中急/亚急性6例),壁内血肿1例(1.8%),主动脉缩窄1例(1.8%)。
  • 部署区域:0区16例(29.1%),1区5例(9.1%),2区34例(61.8%)。
  • 24例(43.6%)术前行主动脉弓去分支,23例(41.8%)术前放置脊髓引流。
  • 技术成功率100%,手术死亡率3.6%(2例),无卒中或瘫痪,1例肾功能衰竭需透析。
  • 中位随访366天(IQR 189-444),内漏发生率16.4%(9例),全因死亡率线性率为11.0%/患者年。

临床怎么用

  • TBE可用于0区、1区及夹层等超适应症解剖条件,但需注意内漏和再次干预风险。
  • 术前脊髓引流和弓部去分支可用于复杂病例的辅助支持。

局限性

  • 单中心回顾性设计,样本量有限(55例),随访时间较短。
  • 缺乏对照组,耐久性需长期随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The first thoracic branched endoprosthesis (TBE) device for arch and proximal descending aortic thoracic endovascular aortic repair (TEVAR) became commercially available in the United States in 2022 (WL Gore, Flagstaff, AZ, United States). The pivotal approval study was limited to zone 2 deployment in cases of aortic aneurysm, but its use in aortic dissections and deployment in zones 0 and 1 remain investigational. We describe early results of Gore TBE device deployment in real-world patients and in a variety of clinical settings including off-label indications. METHODS: Patient characteristics, procedural details, and postoperative outcomes were assessed in this retrospective single-centre cohort study. Twenty-one patients (38.2%) were not open surgical candidates due to comorbidities. Follow-up evaluations included computed tomography angiography imaging of the device and its branches in addition to out. PATIENT: evaluation at discharge, 3 and 12 months, and then annually thereafter. The rate of endoleaks and re-interventions were assessed over the course of follow-up. RESULTS: Between September 2022 and September 2024, 55 consecutive patients underwent aortic repair using the Gore TBE endoprosthesis at our institution. Ten (18.2%) cases were performed in an urgent/emergency setting. Indication for TBE repair was arch, descending and/or thoraco-abdominal aortic aneurysm (N = 26 [47.3%]), dissection (N = 27 [49.1%], 6 acute/subacute), intramural haematoma (N = 1 [1.8%]), or aortic coarctation (N = 1 [1.8%)]. Device deployment was performed in aortic zone 0 (N = 16 [29.1%]), zone 1 (N = 5 [9.1%]), or zone 2 (N = 34 [61.8%]). Twenty-four (43.6%) underwent an aortic arch debranching procedure prior to TEVAR, and 23 (41.8%) had preoperative spinal drain placement. Technical success was 100.0% following the index operation. Operative mortality was 3.6% (N = 2). There were no cases of stroke or paralysis and one case of renal failure requiring dialysis. One patient experienced paraparesis treated with spinal drain placement with immediate resolution. Median follow-up was 366 (interquartile range [IQR]: 189, 444) days. The rate of endoleak over the follow-up period was 16.4% (N = 9). Three cases were treated medically with ongoing surveillance, and the remaining 6 underwent intervention: 5 endovascular, 1 open. The linearized all-cause mortality rate was 11.0% per patient-year. CONCLUSIONS: Real-world use of the Gore TBE device demonstrates its safety and versatility in addressing various aortic pathologies and deployment zones. Further follow-up is necessary to assess the durability of repair, and novel investigational devices may improve outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Lou X, Vargo PR, Caputo F, et al. Initial Post-Commercialization Experience Using a Thoracic Branch Endoprosthesis: Broad Application to Real-World Patients. Eur J Cardiothorac Surg. 2026. PMID: 41408087. doi:10.1093/ejcts/ezaf452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。